TYK2 and systemic lupus erythematosus: Selective inhibition of Tyk2 may provide therapeutic benefit in the treatment of various diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes [9–13].